PPARA and scleroderma: It is interesting that similar observations with reduced pulmonary fibrosis and vasculopathy were also seen in a Sugen-dependent transgenic mouse model of scleroderma-associated pulmonary hypertension using a PPAR agonist with antifibrotic properties [33].